[go: up one dir, main page]

AR055631A1 - Composicion farmaceutica estable de glimepirida con liberacion inmediata y metformina con liberacion prolongada - Google Patents

Composicion farmaceutica estable de glimepirida con liberacion inmediata y metformina con liberacion prolongada

Info

Publication number
AR055631A1
AR055631A1 ARP060103890A ARP060103890A AR055631A1 AR 055631 A1 AR055631 A1 AR 055631A1 AR P060103890 A ARP060103890 A AR P060103890A AR P060103890 A ARP060103890 A AR P060103890A AR 055631 A1 AR055631 A1 AR 055631A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
metformin
immediate release
prolonged
release
Prior art date
Application number
ARP060103890A
Other languages
English (en)
Inventor
Regalado Antonio Santiago
Leon Sixto Serafin Espinoza
Original Assignee
Silanes Sa De Cv Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38042925&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR055631(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Silanes Sa De Cv Lab filed Critical Silanes Sa De Cv Lab
Publication of AR055631A1 publication Critical patent/AR055631A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Composicion farmacéutica en forma de tabletas de estabilidad comprobada, así como su proceso de obtencion, en la cual se tienen dos principios activos consistentes en dos hipoglucemiantes orales: una sulfonilurea como la Glimepirida con liberacion inmediata en una fase y una biguanida como el clorhidrato de Metformina (Metformina HCl) con liberacion prolongada en otra fase, la tableta es para administracion oral preferentemente de una a dos veces al día, en una sola de estas tabletas bifásicas, es posible incluir más de 500mg de Metformina HCl, es decir hasta 1000 mg o 1500 mg, adaptándose segun los requerimientos diarios para cada paciente. La combinacion de estos hipoglucemiantes muestra un efecto sinérgico y por consiguiente una mayor efectividad en el control de los niveles de glucosa en sangre de personas con padecimiento de diabetes mellitus tipo 2. Reivindicacion 1: Una composicion farmacéutica estable en forma de tableta caracterizada por que comprende un nucleo o matriz que contiene una biguanida de liberacion prolongada; una capa o recubrimiento aislante de un polímero hidrofobico; y un recubrimiento que contiene una sulfonilurea de liberacion inmediata.
ARP060103890A 2005-09-08 2006-09-07 Composicion farmaceutica estable de glimepirida con liberacion inmediata y metformina con liberacion prolongada AR055631A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MXPA05009633A MXPA05009633A (es) 2005-09-08 2005-09-08 Composicion farmaceutica estable de glimepirida de liberacion inmediata y metformina de liberacion prolongada.

Publications (1)

Publication Number Publication Date
AR055631A1 true AR055631A1 (es) 2007-08-29

Family

ID=38042925

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103890A AR055631A1 (es) 2005-09-08 2006-09-07 Composicion farmaceutica estable de glimepirida con liberacion inmediata y metformina con liberacion prolongada

Country Status (5)

Country Link
US (1) US20070264331A1 (es)
AR (1) AR055631A1 (es)
BR (1) BRPI0605026A (es)
CO (1) CO5900010A1 (es)
MX (1) MXPA05009633A (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2284829T3 (es) * 2002-01-25 2007-11-16 Laboratorios Silanes, S.A. De C.V. Composicion farmaceutica que se usa para controlar la glucosa en sangre en pacientes con diabetes de tipo 2.
CN101801351B (zh) * 2007-07-19 2012-12-12 武田药品工业株式会社 包含阿格列汀和盐酸二甲双胍的固体制剂
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AU2009210641A1 (en) * 2008-02-05 2009-08-13 Merck Sharp & Dohme Corp. Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-IV inhibitor
EP2242745A1 (de) * 2008-02-07 2010-10-27 Sanofi-Aventis Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
CN101959406A (zh) * 2008-03-04 2011-01-26 默沙东公司 二甲双胍和二肽基肽酶-ⅳ抑制剂的组合的药物组合物
EP2228066A1 (en) 2009-03-03 2010-09-15 LEK Pharmaceuticals d.d. Pharmaceutical compositions of sulphonylurea-based active pharmaceutical ingredient with excellent dissolution properties
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US8581001B2 (en) 2010-04-16 2013-11-12 Codman & Shurtleff Metformin-cysteine prodrug
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
EP2438911A1 (en) 2010-10-08 2012-04-11 LEK Pharmaceuticals d.d. Pharmaceuticals compositions comprising sulphonylurea-class insulin secretagogue and polyethylene glycol castor oil
AU2011342893A1 (en) 2010-12-13 2013-05-02 Purdue Pharma L.P. Controlled release dosage forms
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
MX339374B (es) * 2011-04-29 2016-05-13 Inst De Investigación En Química Aplic S A De C V Cocristales ionicos con base en metformina.
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3072527A (en) * 1959-07-01 1963-01-08 Horner Frank W Ltd Use of tolbutamide in the treatment of acne
JP3465247B2 (ja) * 1992-12-28 2003-11-10 アベンティス ファーマ株式会社 動脈硬化症の予防および治療剤
DE4432757A1 (de) * 1994-09-14 1996-03-21 Boehringer Mannheim Gmbh Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
US6348469B1 (en) * 1995-04-14 2002-02-19 Pharma Pass Llc Solid compositions containing glipizide and polyethylene oxide
US6011049A (en) * 1997-02-19 2000-01-04 Warner-Lambert Company Combinations for diabetes
ES2216335T3 (es) * 1997-12-08 2004-10-16 Bristol-Myers Squibb Company Nuevas sales de metformina y procedimiento.
SI0974356T1 (en) * 1998-07-15 2003-12-31 Merck Sante Tablets comprising a combination of metformin and glibenclamide
RU2003104808A (ru) * 2000-08-07 2004-08-20 Ранбакси Сигниче Ллк (Us) Жидкий состав метформина
MXPA03006217A (es) * 2001-01-12 2004-10-15 Sun Pharmaceutical Ind Ltd Sistema de administracion espaciada de farmacos.
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
ES2284829T3 (es) * 2002-01-25 2007-11-16 Laboratorios Silanes, S.A. De C.V. Composicion farmaceutica que se usa para controlar la glucosa en sangre en pacientes con diabetes de tipo 2.
US6682759B2 (en) * 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
CN1729005A (zh) * 2002-11-15 2006-02-01 兰贝克赛实验室有限公司 含双胍－磺酰脲类组合的药物剂型
US20050013863A1 (en) * 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs

Also Published As

Publication number Publication date
MXPA05009633A (es) 2007-03-07
CO5900010A1 (es) 2008-03-31
BRPI0605026A (pt) 2007-04-17
US20070264331A1 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
AR055631A1 (es) Composicion farmaceutica estable de glimepirida con liberacion inmediata y metformina con liberacion prolongada
ES2507491T3 (es) Preparación farmacéutica que comprende un inhibidor de DPP-IV y otros agentes terapéuticos de la diabetes en forma concomitante o combinada
CL2008000823A1 (es) Formulacion farmaceutica de liberacion inmediata que comprende dapagliflozina propilenglicol hidrato y un portador farmaceuticamente aceptable; uso para tratar diabetes, intolerancia a la glucosa, resistencia a la insulina, entre otras.
NL300889I2 (nl) Trifluridine in combinatie met tipiracilhydrochloride
ES2577930T3 (es) Derivados de triazina para retrasar el inicio de la diabetes tipo 1
AR037407A1 (es) Composiciones farmaceuticas para el tratamiento de la diabetes mellitus de tipo ii
ECSP10010395A (es) Formulacion de capsula
EA200900626A1 (ru) Комбинированное лечение ингибиторами sglt-2 (натрийзависимый сопереносчик глюкозы 2) и содержащими их фармацевтическими композициями
AR030557A1 (es) Una tableta en multicapa de liberacion controlada y metodo de tratamiento
BRPI0516237A (pt) derivado de pirimidina fundido com anel não aromático
MA28921B1 (fr) Derive heterocyclique azote et medicament le contenant en tant que principe actif
AR038527A1 (es) Forma de dosificacion que contiene un inhibidor de la pde 4 como ingrediente activo
DK1680128T3 (da) Myo-inositolhexaphosphat til topisk anvendelse
EP1602362A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING ACTIVE INGREDIENTS HAVING A HIGH CONCENTRATION ON A BALL-MOLDED CORE
MA28862B1 (fr) Composition pharmaceutique sous forme de comprime a residence gastrique contenant un principe actif
ECSP077843A (es) Tratamiento o prevención del prurito
ATE361065T1 (de) Pharmazeutische zusammensetzung zur kontrolle des blutzuckers bei patienten mit typ 2 diabetes
ATE361743T1 (de) Beschichtete minitabletten von venlafaxinhydrochlorid mit verlängerter freisetzung
BRPI0613447A2 (pt) composição farmacêutica, usos de um agonista de ppargama e de um agente biguanida, e, kit para evitar ocorrência de efeitos colaterais adversos devido à ação de um agente biguanida no tratamento do diabetes
ATE460934T1 (de) Pharmazeutische zubereitungen von ciprofloxacin
AR013261A1 (es) Formulaciones farmaceuticas para analogos de camptotecina en capsula de gelatina
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
ECSP11010999A (es) Combinación de dosis fija en la forma de una tableta de dos capas o de una sola capa de alisquireno y amlodipina
AR041856A1 (es) Tabletas de liberacion retardada de administracion por via oral y metodos de fabricacion y uso de las mismas
WO2006122069A3 (en) Formulations of mast cell stabilizing agents for delivery to the colon

Legal Events

Date Code Title Description
FB Suspension of granting procedure
FC Refusal